Calcineurin and hypertrophic heart disease: novel insights and remaining questions.

[1]  Y. Zou,et al.  Isoproterenol Activates Extracellular Signal–Regulated Protein Kinases in Cardiomyocytes Through Calcineurin , 2001, Circulation.

[2]  Feng Chen,et al.  Signals Transduced by Ca2+/Calcineurin and NFATc3/c4 Pattern the Developing Vasculature , 2001, Cell.

[3]  S. Sasayama,et al.  Calcineurin Pathway Is Required for Endothelin-1—Mediated Protection Against Oxidant Stress—Induced Apoptosis in Cardiac Myocytes , 2001, Circulation research.

[4]  J. Molkentin.  Calcineurin, mitochondrial membrane potential, and cardiomyocyte apoptosis. , 2001, Circulation research.

[5]  E. Olson,et al.  Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy , 2001, The EMBO journal.

[6]  P. Buttrick,et al.  PKC-β is not necessary for cardiac hypertrophy , 2001 .

[7]  R. Hajjar,et al.  Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Rick B. Vega,et al.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Hajjar,et al.  Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure , 2001, Circulation.

[10]  J. Neal,et al.  Glycogen Synthase Kinase-3 Inhibits the DNA Binding Activity of NFATc* , 2001, The Journal of Biological Chemistry.

[11]  J. Molkentin,et al.  Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway. , 2001, Journal of molecular and cellular cardiology.

[12]  T. Pedrazzini,et al.  Calcineurin Blockade Prevents Cardiac Mitogen-activated Protein Kinase Activation and Hypertrophy in Renovascular Hypertension* , 2000, The Journal of Biological Chemistry.

[13]  E. Olson,et al.  Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Olson,et al.  Making matters worse for a broken heart. , 2000, The Journal of clinical investigation.

[15]  E. Olson,et al.  Independent Signals Control Expression of the Calcineurin Inhibitory Proteins MCIP1 and MCIP2 in Striated Muscles , 2000, Circulation research.

[16]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[17]  James O. Mudd,et al.  An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .

[18]  S. Ogawa,et al.  Calmodulin Kinases II and IV and Calcineurin Are Involved in Leukemia Inhibitory Factor–Induced Cardiac Hypertrophy in Rats , 2000, Circulation research.

[19]  Y. Hiroi,et al.  β-Adrenergic Pathway Induces Apoptosis through Calcineurin Activation in Cardiac Myocytes* , 2000, The Journal of Biological Chemistry.

[20]  Shigeo Koyasu,et al.  Two distinct action mechanisms of immunophilin–ligand complexes for the blockade of T‐cell activation , 2000, EMBO reports.

[21]  M. Hori,et al.  Calcineurin Inhibitor Attenuates Left Ventricular Hypertrophy, Leading to Prevention of Heart Failure in Hypertensive Rats , 2000, Circulation.

[22]  T. Hewett,et al.  Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[23]  S. Kudoh,et al.  Calcineurin Inhibitor Attenuates the Development and Induces the Regression of Cardiac Hypertrophy in Rats With Salt-Sensitive Hypertension , 2000, Circulation.

[24]  K. Chien.  Genomic circuits and the integrative biology of cardiac diseases , 2000, Nature.

[25]  J. Qin,et al.  Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. , 2000, Molecular cell.

[26]  D. Warshaw,et al.  In Vivo Analysis of an Essential Myosin Light Chain Mutation Linked to Familial Hypertrophic Cardiomyopathy , 2000, Circulation research.

[27]  B. Lorell,et al.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis. , 2000, Circulation.

[28]  C. Grozinger,et al.  Calcium Regulates Transcriptional Repression of Myocyte Enhancer Factor 2 by Histone Deacetylase 4* , 2000, The Journal of Biological Chemistry.

[29]  S. Lehnart,et al.  Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium. , 2000, Cardiovascular research.

[30]  X. Estivill,et al.  DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. , 2000, Human molecular genetics.

[31]  Y. Kihara,et al.  Cardiac calcineurin during transition from hypertrophy to heart failure in rats. , 2000, Biochemical and biophysical research communications.

[32]  R. Kerber,et al.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. , 2000, Circulation.

[33]  O. Clausen,et al.  Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. , 2000, American journal of physiology. Heart and circulatory physiology.

[34]  J. Molkentin,et al.  Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. , 2000, Circulation.

[35]  Y. Zou,et al.  Ca2+/Calmodulin-dependent Kinase II and Calcineurin Play Critical Roles in Endothelin-1-induced Cardiomyocyte Hypertrophy* , 2000, The Journal of Biological Chemistry.

[36]  R. Passier,et al.  CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. , 2000, The Journal of clinical investigation.

[37]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[38]  M. Hixon,et al.  Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. , 2000, Circulation.

[39]  Juan Miguel Redondo,et al.  A Role for the p38 MAP Kinase Pathway in the Nuclear Shuttling of NFATp* , 2000, The Journal of Biological Chemistry.

[40]  J. Molkentin,et al.  Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart , 2000, The Journal of Biological Chemistry.

[41]  E. Olson,et al.  MEF2 responds to multiple calcium‐regulated signals in the control of skeletal muscle fiber type , 2000, The EMBO journal.

[42]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[43]  Mark A Sussman,et al.  Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. , 2000, Journal of molecular and cellular cardiology.

[44]  Weiya Ma,et al.  Involvement of Nuclear Factor of Activated T Cells Activation in UV Response , 2000, The Journal of Biological Chemistry.

[45]  Rick B. Vega,et al.  A Protein Encoded within the Down Syndrome Critical Region Is Enriched in Striated Muscles and Inhibits Calcineurin Signaling* , 2000, The Journal of Biological Chemistry.

[46]  G. Condorelli,et al.  Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. , 2000, Circulation research.

[47]  J. Molkentin,et al.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Barber,et al.  Inhibition of Calcineurin Phosphatase Activity by a Calcineurin B Homologous Protein* , 1999, The Journal of Biological Chemistry.

[49]  Y. Zou,et al.  Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. , 1999, Circulation.

[50]  S. Daniels,et al.  Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. , 1999, The American journal of pathology.

[51]  A. Nordheim,et al.  Ca2+-induced p38/SAPK signalling inhibited by the immunosuppressant cyclosporin A in human peripheral blood mononuclear cells. , 1999, European journal of biochemistry.

[52]  D. Kass,et al.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.

[53]  J. Lotem,et al.  Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Hewett,et al.  Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[55]  J. Guerrero,et al.  Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. , 1999, The Journal of clinical investigation.

[56]  J. Lorenz,et al.  Abnormal Cardiac Structure and Function in Mice Expressing Nonphosphorylatable Cardiac Regulatory Myosin Light Chain 2* , 1999, The Journal of Biological Chemistry.

[57]  A. Rao,et al.  NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  E R Kandel,et al.  A selective role of calcineurin aalpha in synaptic depotentiation in hippocampus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Borg,et al.  Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. , 1999, Circulation research.

[60]  E. Olson,et al.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. , 1999, Circulation research.

[61]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[62]  V. Cairns,et al.  Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. , 1999, Transplantation.

[63]  J. Molkentin,et al.  Calcineurin and human heart failure , 1999, Nature Medicine.

[64]  P. Gluckman,et al.  Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system , 1999, Progress in Neurobiology.

[65]  D. H. Kim,et al.  Cyclosporin A treatment alters characteristics of Ca2+-release channel in cardiac sarcoplasmic reticulum. , 1999, American journal of physiology. Heart and circulatory physiology.

[66]  Roger J. Davis,et al.  Requirement for Transcription Factor NFAT in Interleukin-2 Expression , 1999, Molecular and Cellular Biology.

[67]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[68]  E. Neer,et al.  Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[69]  B. Carabello,et al.  Calcineurin Inhibition and Cardiac Hypertrophy , 1998, Science.

[70]  T. Hewett,et al.  A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[71]  K. Walsh,et al.  Calcineurin inhibitors and cardiac hypertrophy , 1998, Nature Medicine.

[72]  Mark A Sussman,et al.  Prevention of cardiac hypertrophy in mice by calcineurin inhibition. , 1998, Science.

[73]  John W. Adams,et al.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Boivin,et al.  β-Tropomyosin Overexpression Induces Severe Cardiac Abnormalities , 1998 .

[75]  S. Snyder,et al.  Cain, A Novel Physiologic Protein Inhibitor of Calcineurin* , 1998, The Journal of Biological Chemistry.

[76]  H. Youn,et al.  Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. , 1998, Immunity.

[77]  M. Karin,et al.  Calcineurin preferentially synergizes with PKC‐θ to activate JNK and IL‐2 promoter in T lymphocytes , 1998, The EMBO journal.

[78]  G. Dorn,et al.  Decompensation of Pressure-Overload Hypertrophy in Gαq-Overexpressing Mice , 1998 .

[79]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[80]  Tak W. Mak,et al.  Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum , 1998, Nature.

[81]  Michael J. Grusby,et al.  The transcription factor NF-ATc is essential for cardiac valve formation , 1998, Nature.

[82]  M. Matzuk,et al.  Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12 , 1998, Nature.

[83]  L. Kedes,et al.  Altered expression of tropomodulin in cardiomyocytes disrupts the sarcomeric structure of myofibrils. , 1998, Circulation research.

[84]  T. Hewett,et al.  Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. , 1998, The Journal of clinical investigation.

[85]  M Dickens,et al.  Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. , 1997, Science.

[86]  G. Fishman,et al.  Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. , 1997, The Journal of clinical investigation.

[87]  T. Hewett,et al.  Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. , 1997, The Journal of clinical investigation.

[88]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[89]  J. Fewell,et al.  A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. , 1997, The American journal of physiology.

[90]  E. Lakatta,et al.  Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. , 1997, Circulation research.

[91]  C. Malécot,et al.  In vivo and in vitro inhibition of the L-type calcium current in isolated guinea-pig cardiomyocytes by the immunosuppressive agent cyclosporin A. , 1997, Journal of molecular and cellular cardiology.

[92]  Christopher C. Goodnow,et al.  Differential activation of transcription factors induced by Ca2+ response amplitude and duration , 1997, Nature.

[93]  J. Seidman,et al.  Cytoskeletal Changes in the Brains of Mice Lacking Calcineurin Aα , 1997, Journal of neurochemistry.

[94]  R. Tuan,et al.  Function of FK506 binding protein (FKBP) in chick embryonic cardiac development. , 1997, Heart and vessels.

[95]  H. Ehmke,et al.  Dissociation of left ventricular hypertrophy, beta-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. , 1997, Circulation.

[96]  Minoru Hongo,et al.  MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.

[97]  Martin R. Hodge,et al.  NF-AT-Driven Interleukin-4 Transcription Potentiated by NIP45 , 1996, Science.

[98]  D. Barber,et al.  A calcineurin homologous protein inhibits GTPase-stimulated Na-H exchange. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Laurie H Glimcher,et al.  The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4 , 1996, Cell.

[100]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[101]  J. Fewell,et al.  Transgenic remodeling of the contractile apparatus in the mammalian heart. , 1996, Circulation research.

[102]  F. Alt,et al.  T cell responses in calcineurin A alpha-deficient mice , 1996, The Journal of experimental medicine.

[103]  G. Boivin,et al.  Molecular and Physiological Effects of Overexpressing Striated Muscle β-Tropomyosin in the Adult Murine Heart (*) , 1995, The Journal of Biological Chemistry.

[104]  S. Snyder,et al.  Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux , 1995, Cell.

[105]  Jonathan Weber,et al.  Cyclosporin A , 1995, Nature.

[106]  J. W. Rooney,et al.  Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene. , 1995, Immunity.

[107]  L. Langeberg,et al.  Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. , 1995, Science.

[108]  T. Kuno,et al.  cDNA cloning of an alternatively spliced isoform of the regulatory subunit of Ca2+/calmodulin-dependent protein phosphatase (calcineurin B alpha 2). , 1994, Biochimica et biophysica acta.

[109]  William Arbuthnot Sir Lane,et al.  Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. , 1993, Science.

[110]  M. F. Shannon,et al.  The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[111]  R. Kincaid,et al.  Structure and expression of two isoforms of the murine calmodulin-dependent protein phosphatase regulatory subunit (calcineurin B). , 1992, Biochemical and biophysical research communications.

[112]  G. Crabtree,et al.  Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation , 1992, Nature.

[113]  Y. Kihara,et al.  Altered calcium handling in left ventricular pressure-overload hypertrophy as detected with aequorin in the isolated, perfused ferret heart. , 1991, Circulation research.

[114]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[115]  D. Armstrong.  Calcium channel regulation by calcineurin, a Ca2+-activated phosphatase in mammalian brain , 1989, Trends in Neurosciences.

[116]  G. Crabtree,et al.  Identification of a putative regulator of early T cell activation genes. , 1988, Science.

[117]  Hans Michael Piper,et al.  Cardiovascular Research , 1966, British medical bulletin.

[118]  A. Wear.  CIRCULATION , 1964, The Lancet.

[119]  S. Kudoh,et al.  Weidong Zhu , Sumiyo Hypertrophy Induced Cardiac − Calcineurin Plays a Critical Role in the Development of Pressure Overload , 2001 .

[120]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[121]  D. Ganten,et al.  Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. , 2000, Hypertension.

[122]  A. Musarò,et al.  Research news , 2000, Nature Medicine.

[123]  M. Murata,et al.  Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, enhances L-type Ca2+ current and [Ca2+]i transient in cardiomyocytes. , 1999, Journal of molecular and cellular cardiology.

[124]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[125]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[126]  J. Morgan,et al.  Abnormal intracellular calcium handling in acute and chronic heart failure: role in systolic and diastolic dysfunction. , 1990, European heart journal.